R&D Progress

T-E Pharma’s subsidiary, Immunwork, Inc., announced that its proprietary ultralong-acting GLP-1 receptor agonist (GLP-1 RA), TE-8105, has received approval from an Australian Human Research Ethics Committee (HREC), officially enabling the initiation of its Phase 2b clinical trial. This milestone marks an important step forward in Immunwork’s development of long-acting peptide therapeutics and represents TE-8105’s transition

“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 115IDX02001.

Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), TE-8105, developed for the treatment of obesity. Conducted in Australia, the study demonstrated that TE-8105 is safe, well tolerated, and exhibits clear weight-loss potential, with only mild adverse

• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection site reactions seen with current therapies.• Strong Pharmacodynamic Activity: Robust, dose-dependent reduction of disease biomarker IGF-1, with 83% of high-dose participants achieving a >20% reduction, confirming therapeutic potential.• Significant Market Potential: Positioned for the US$10 billion long-acting

Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian Human Research Ethics Committee in May. TE-8105 targets obesity (including weight management), type 2 diabetes, and fatty liver disease, while TE-8214 targets neuroendocrine tumors and acromegaly. Both drugs have undergone initial dosing in low-dose subjects,

“The development of the novel drug, TE-8105, the glucagon-like peptide-1 receptor agonist” was selected as a significant case of the Center for Drug Evaluation (CDE), Taiwan. The CDE case number is 110IDX04007.